Author | Lightnews

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Jul 16

To Screen—or not to screen for
for advanced steatotic liver disease that’s the question?

Our new @lancetgastrohep.bsky.social
review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria
@Stine Johansen

authors.elsevier.com/c/1lRV98nByr...

1 3

Reposted

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Jul 16

New Review - Screening for advanced steatotic liver disease

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social

Screening for advanced steatotic liver disease

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...

www.thelancet.com

4 4

Reposted

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Mar 31

APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol"

www.nature.com/articles/s41...

#Liversky

Fig. 4: The bidirectional linking of factors that predispose to steatotic liver disease.

2 4

Reposted

Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Mar 31

Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more!

www.nature.com/nrgastro/vol...

Steatotic liver disease burden paradox, inspired by the Perspective on p281.

4 5 13

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Apr 25

🧪 New findings published in @jhepatology.bsky.social JHEP reports benchmarking several biomarkers and combinations hereof show soluble TREM2, PRO-C3 & HOMA-IR effectively reflect histological disease activity in MASLD/MASH patients in response to treatment.

doi.org/10.1016/j.jh...

1

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Apr 16

Why do some patients remain healthy while others develop severe liver complications despite having the exact same genetic mutation in Alpha-1 Antitrypsin Deficiency?

Proud of being part of this project - Deep Visual Proteomics at single cell level
👉in @nature.com

www.nature.com/articles/s41...

1 4

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Apr 14

Check out the “Steatotic Liver Disease Burden Paradox “
pubmed.ncbi.nlm.nih.gov/39639157/

1

Reposted

Mads Israelsen @israelsenm.bsky.social · Apr 8

Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️

Over 60% with MetALD/ALD and 38% with MASLD change subclass.

This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐

Link: www.cghjournal.org/article/S154...

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments

Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...

www.cghjournal.org

1 1 8

Reposted

Maja Thiele @majathiele.bsky.social · Feb 17

We made the cover of Hepatology 👏👏
@aleksanderkrag.bsky.social #LiverSky

journals.lww.com/hep/fulltext...

3 18

Reposted

EASL @easlnews.bsky.social · Feb 5

In today’s #readoftheweek📚 learn why accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with #steatoticliverdisease & when designing clinical trials.

Read now: www.jhep-reports.eu/article/S258...

🙏 @aleksanderkrag.bsky.social @majathiele.bsky.social et al.

2 4

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Jan 31

#EASL Studio season 8 starts next week, we will discuss Steatotic Liver Disease - how the current breakthroughs will transform clinical practice. Want to stay updated join us.!

easl.eu/easl-studio-...

2 5

Reposted

Mads Israelsen @israelsenm.bsky.social · Jan 29

AlbTrial Update

🏥 70 out of 240 included

But what is AlbTrial?

AlbTrial is one of the most ambitious RCTs in the field of decompensated cirrhosis.

🔗 bmjopen.bmj.com/content/bmjo...

🧵below

Annual General Assembly in MicrobPredict #liversky #cirrhosis

1 1 6

Reposted

Rob Brierley @robbrierley.bsky.social · Jan 22

What impact do reporting discrepancies in alcohol intake have on the estimated prevalence of MetALD and alcohol-related liver disease?

@aleksanderkrag.bsky.social and colleagues discuss…

www.thelancet.com/journals/lan...

#GastroSky #MedSky

Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD

For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic lipid metabolism, causing steatosis, can result from several factors predomin...

www.thelancet.com

2 9

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Jan 22

Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD - MASLD VS MetALD/ALD is not 10:1 - more likely 1:1😳

- The Lancet Gastroenterology & Hepatology www.thelancet.com/journals/lan...

1

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Jan 16

Joined a great meeting in Helsinki recently and had the pleasure of seeing but not understanding the new nomenclature of Steatotic liver disease in Finnish😀

3

Reposted

EASL @easlnews.bsky.social · Jan 15

2025 is the perfect year to take your career to the next level🚀

There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.

Apply by 20 January: easl.eu/leadership25

#LiverSky

5 12

Reposted

Tom Hemming Karlsen @tomhemmingk.bsky.social · Dec 10

Two days of finalizing the narrative and recommendations of the second EASL @thelancet.bsky.social Commission in Geneva. Now we write the report! @aleksanderkrag.bsky.social

3 11

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Dec 13

EASL Governing Board meeting - working for the community❤️
👉SLD and LCS summits
👉EASL schools / what and where?
👉EiC @JHepatology @JHEP_Reports new initiatives🤩
👉 X vs @bluesky ?
👉AI Task Force
👉#EASLCongress 2025 Amsterdam
👉Register grants
👉Global collaboration

4 10

aleksanderkrag.bsky.social @aleksanderkrag.bsky.social · Dec 7

@EASL @AASLD MASTERCLASS in beautiful Savannah ❤️

Gathering of next generation of leaders in hepatology🤩🤩

👉team science
👉building a team

Networking